Polaryx Therapeutics, Inc. (Form: 3, Received: 01/29/2026 18:08:11)

FORM 3	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES	OMB APPROVAL OMB Number: 3235-0104 Estimated average burden hours per response... 0.5
	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person ^*

Yang Alex Keun Mo

2. Date of Event Requiring Statement (MM/DD/YYYY) 1/29/2026

3. Issuer Name and Ticker or Trading Symbol

Polaryx Therapeutics, Inc. [PLYX]

(Last) (First) (Middle)

SOUTH TOWER, 140 E RIDGEWOOD AVENUE,, SUITE 415

4. Relationship of Reporting Person(s) to Issuer (Check all applicable)

__X__ Director ___X___ 10% Owner
___X___ Officer (give title below) _____ Other (specify below)
Chief Executive Officer /

(Street)

PARAMUS, NJ 07652

(City) (State) (Zip)

5. If Amendment, Date Original Filed(MM/DD/YYYY)

6. Individual or Joint/Group Filing(Check Applicable Line)

___ Form filed by One Reporting Person
_X_ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	1,400,000 ⁽¹⁾	D
Common Stock	22,452,954	I	By Mstone Partners Healthcare Limited ⁽²⁾
Common Stock	183,560	I	By MBstone Biotech Flagship Limited ⁽³⁾
Common Stock	108,282	I	By Mstone Pediaorphan Singapore I Pte. Limited ⁽⁴⁾

*Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)*
1. Title of Derivate Security (Instr. 4)	2. Date Exercisable and Expiration Date (MM/DD/YYYY)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivate Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security		6. Nature of Indirect Beneficial Ownership (Instr. 5)

Explanation of Responses:
(1)	Includes (i) 148,500 restricted stock units ("RSUs"), which will vest on March 1, 2026, (ii) 330,000 RSUs, which will vest in two equal installments on November 1, 2026 and November 1, 2027 and (iii) 450,000 RSUs, which will vest in four equal installments on September 1, 2026, September 1, 2027, September 1, 2028 and September 1, 2029, in each case subject to the Reporting Person's continued service to the Issuer or its subsidiaries, Mstone Partners Healthcare Limited ("Mstone") or its affiliates, or Curestone Partners Platform Limited or its affiliates. The RSUs are not deliverable unless and until the Issuer consummates a change in control within seven years of the grant date of such RSUs.
(2)	Alex Keun Mo Yang is the founder and Chief Executive Officer of Mstone. Mr. Yang disclaims beneficial ownership over any of the reported securities, except to the extent of his pecuniary interest therein.
(3)	Mr. Yang is the Chief Executive Officer of MBstone Biotech Flagship Limited. Mr. Yang disclaims beneficial ownership over any of the reported securities, except to the extent of his pecuniary interest therein.
(4)	Mr. Yang is the Chief Executive Officer of Mstone Pediaorphan Singapore I Pte. Limited. Mr. Yang disclaims beneficial ownership over any of the reported securities owned, except to the extent of his pecuniary interest therein.

Remarks:
Exhibit 24 - Power of Attorney

Mstone, MBstone Biotech Flagship Limited and Mstone Pediaorphan Singapore I Pte. Limited may each be deemed a director by deputization of the Issuer by virtue of the fact that Mr. Yang serves on the board of directors of the Issuer and is the Chief Executive Officer of each of the entities.

Reporting Owners
Reporting Owner Name / Address	Relationships
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
Yang Alex Keun Mo SOUTH TOWER, 140 E RIDGEWOOD AVENUE, SUITE 415 PARAMUS, NJ 07652	X	X	Chief Executive Officer
Mstone Partners Healthcare Ltd 7/F, 80 GLOUCESTER ROAD WANCHAI, K3	X	X

Signatures
/s/ Alex Keun Mo Yang		1/29/2026
^**Signature of Reporting Person		Date
/s/ Alex Keun Mo Yang, Chief Executive Officer of Mstone Partners Healthcare Limited		1/29/2026
^**Signature of Reporting Person		Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
*	If the form is filed by more than one reporting person, see Instruction 5(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note:	File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Exhibit 24

POWER OF ATTORNEY

Know all by these presents that the undersigned hereby constitutes and appoints each of Alex Yang, G. Michael Landis and Valerie Yeung, and any of their substitutes, signing singly, as the undersigned’s true and lawful attorney-in-fact to:

execute for and on behalf of the undersigned, in the undersigned’s capacity as a director and/or officer of Polaryx Therapeutics, Inc. (the “Company”), Forms 3, 4, and 5 in accordance with Section 16(a) of the Securities Exchange Act of 1934, as amended, and the rules thereunder;

do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Form 3, 4, or 5, complete and execute any amendment or amendments thereto, and timely file such form with the U.S. Securities and Exchange Commission and any securities exchange or similar authority; and

take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact’s discretion.

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that each such attorney-in-fact, or such attorney-in-fact’s substitute or substitutes, shall lawfully do or cause to be done by virtue of this Power of Attorney and the rights and powers herein granted. The undersigned also ratifies hereby any action previously taken by each such attorney-in-fact that would have been authorized by this Power of Attorney if it had been in effect at the time such action was taken. The undersigned acknowledges that each attorney-in-fact, in serving in such capacity at the request of the undersigned, is not assuming, nor is the Company assuming, any of the undersigned’s responsibilities to comply with Section 16 of the Securities Exchange Act of 1934, as amended.

This Power of Attorney shall remain in full force and effect until the earliest of: (a) the undersigned is no longer required to file Forms 3, 4, and 5 with respect to the undersigned’s holdings of and transactions in securities issued by the Company, (b) revocation by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact, or (c) as to any attorney-in-fact, individually, until such attorney-in-fact is no longer employed by the Company or its subsidiaries or Gibson, Dunn & Crutcher LLP, as applicable.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of November 27, 2025.

	/s/ Alex Keun Mo Yang
	Alex Keun Mo Yang